ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1919 • ACR Convergence 2021

    Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis

    Denis Poddubnyy1, Fabian Proft2, Kay-Geert Hermann2, Laura Spiller2, Stefan Niehues2, Lisa Adams2, Mikhail Protopopov2, Valeria Rios Rodriguez2, Burkhard Muche2, Judith Rademacher2, Murat Torgutalp2, Keno Bressem2 and Janis Vahldiek2, 1Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 2Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method for the diagnosis of axial spondyloarthritis (axial SpA). In many…
  • Abstract Number: 1895 • ACR Convergence 2021

    Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry

    Nevin Hammam, Jing Li, Julia L Kay, Jinoos Yazdany and Gabriela Schmajuk, University of California San Francisco, San Francisco, CA

    Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…
  • Abstract Number: 1751 • ACR Convergence 2021

    Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

    Anca Askanase1, Simrat Randhawa2, Laura Lisk3 and Paola Mina-Osorio4, 1Columbia University Medical Center, New York, NY, 2Aurinia Pharmaceuticals Inc., Seattle, WA, 3Aurinia Pharmaceuticals Inc., Victoria, ON, Canada, 4Aurinia Pharmaceuticals Inc., New York, NY

    Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adult patients with active lupus nephritis in combination with background immunosuppressive therapy.…
  • Abstract Number: 1559 • ACR Convergence 2021

    Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India

    Arun Tiwari1, Suma Balan2, Abdul Rauf3, Mahesh kappanayil2, Sajith Kesavan2, Suchitra Sivadas2, Pranav Chickermane2, Ajay Vijayan2, Manu Raj2, Anilkumar V2 and Abish Sudhakar2, 1Amrita Institute of Medical Sciences, Ernakulam, India, 2Amrita Institute of Medical Sciences, Kochi, India, 3Baby Memorial Hospital, Kozikode, India

    Background/Purpose: COVID-19 related multisystem inflammatory syndrome in children (MIS-C) has varied clinical presentation ranging from fever with mild gastrointestinal and/or mucocutaneous changes to life threatening…
  • Abstract Number: 1945 • ACR Convergence 2021

    Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies

    Xenofon Baraliakos1, Roberto Ranza2, Andrew Ostor3, Francesco Ciccia4, Laura Coates5, Simona Rednic6, Jessica Walsh7, Tianming Gao8, Apinya Lertratanakul8, In-Ho Song8, Fabiana Ganz8, Kevin Douglas8 and Atul Deodhar9, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, 3Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, 4University of Campania Luigi Vanvitelli, Napoli, Italy, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 6Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, 7Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 8AbbVie Inc., North Chicago, IL, 9Oregon Health & Science University, Portland, OR

    Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
  • Abstract Number: PP06 • ACR Convergence 2021

    Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) /  My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.

    Michael Linn1 and Dan Smith2, 1Relapsing Polychondritis Foundation, New York, NY, 2Relapsing Polychondritis Foundation, Canton, MI

    Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
  • Abstract Number: PP07 • ACR Convergence 2021

    How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic

    Wigna Cruz, Puerto Rico

    Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
  • Abstract Number: PP05 • ACR Convergence 2021

    Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

    Michael Linn1, Spenser Mestel2 and Susie Ratledge3, 1Relapsing Polychondritis Foundation, New York, NY, 2New York, NY, 3Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN

    Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
  • Abstract Number: PP04 • ACR Convergence 2021

    Dual Roles: Thriving with SLE as a Medical Student

    Chieh Lo1 and Song-Chou Hsieh2, 1School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), 2Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
  • Abstract Number: 1946 • ACR Convergence 2021

    Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial

    Silje Watterdal Syversen1, Guro Goll1, Kristin Jørgensen2, Marthe Brun1, Øystein Sandanger3, Kristin Hammersbøen2, Joseph Sexton1, Inge Olsen3, Johanna Gehin4, David Warren3, Rolf Anton Klaasen3, Trude Bruun5, Maud Kristine Ljoså6, Anne Haugen7, Rune Njålla8, Brigitte Michelsen9, Camilla Zettel10, Yngvill Bragenes11, Svanaug Skorpe12, Eldri Strand13, Pawel Mielnik14, Cato Mørk15, Tore Kvien1, Jørgen Jahnsen2, Nils Bolstad16 and Espen Haavardsholm1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Akershus University Hospital, Lørenskog, Norway, 3Oslo University Hospital, Oslo, Norway, 4Oslo University Hospital, Lillehammer, Nepal, 5The University Hospital of North Norway, Tromsø, Norway, 6Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, 7Østfold Hospital Trust, Moss, Norway, 8Nordland Hospital Trust, Bodø, Bodø, Norway, 9Hospital of Southern Norway Trust, Kristiansand, Norway, 10Betanien Hospital, Skien, Norway, 11Vestre Viken Hospital Trust, Drammen, Norway, 12Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, 13Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 14Førde Hospital Trust, Førde, Norway, 15Akershus Dermatology Center, Lørenskog, Norway, 16Oslo University Hospital, Radiumhospitalet, Oslo, Norway

    Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
  • Abstract Number: PP13 • ACR Convergence 2021

    CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease

    Chantelle Marcial, Boston, MA

    Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
  • Abstract Number: PP12 • ACR Convergence 2021

    Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic

    Guadalupe Torres1, Courtney Wells2 and Kristine Carandang3, 1, 2University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, 3Global Healthy Living Foundation, CreakyJoints, San Diego, CA

    Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
  • Abstract Number: 1944 • ACR Convergence 2021

    Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study

    Josef Smolen1, Paul Bergmans2, Kurt de Vlam3, Elisa Gremese4, Beatriz Joven-Ibáñez5, Tatiana Korotaeva6, Wim Noël7, Michael Nurmohamed8, Petros Sfikakis9, Stefan Siebert10, Elke Theander11 and Laure Gossec12, 1Medical University of Vienna, Vienna, Austria, 2Janssen-Cilag BV, Breda, Netherlands, 3University Hospitals Leuven, Leuven, Belgium, 4Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 5University Hospital 12 de Octubre, Madrid, Spain, 6VA Nasonova Research Institute of Rheumatology, Moscow, Russia, 7Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, 8Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, 9National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 10University of Glasgow, Glasgow, United Kingdom, 11Janssen Cilag, Lund, Sweden, 12Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
  • Abstract Number: PP03 • ACR Convergence 2021

    Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic

    Ida Hakkarinen, Greenbelt, MD

    Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
  • Abstract Number: 1943 • ACR Convergence 2021

    Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial

    Xenofon Baraliakos1, Effie Pournara2, Laura Coates3, Victoria Navarro-Compán4, Roisin White5, Barbara Schulz2 and Robert Landewé6, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 4Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, 5Novartis Ireland Limited, Dublin, Ireland, 6Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands

    Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…
  • « Previous Page
  • 1
  • …
  • 637
  • 638
  • 639
  • 640
  • 641
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology